Exelixis
Biopharmaceutical company focused on discovering, developing and commercializing oncology therapies. Operates multi‑modality discovery and development capabilities spanning small molecules and biotherapeutics (including antibody‑drug conjugates and bispecifics), sponsors global clinical trials across Phases 1–3, and extends reach through strategic licensing and collaboration partnerships.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US-12486233-B2
View Details
Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US-12486233-B2
View DetailsProducts
Cabozantinib (small molecule TKI)
Oral tyrosine kinase inhibitor developed and commercialized for multiple oncology indications; used in combination regimens in clinical development.
Cobimetinib (MEK inhibitor)
Internally discovered MEK pathway inhibitor that has been out‑licensed for development and commercialization.
Esaxerenone (mineralocorticoid receptor blocker)
Oral non‑steroidal selective mineralocorticoid receptor blocker developed via collaboration.
CABOMETYX
CABOMETYX (cabozantinib) is an oral targeted cancer therapy and multikinase inhibitor developed by Exelixis.
COMETRIQ
COMETRIQ (cabozantinib) is a prescription medicine used to treat advanced medullary thyroid cancer.
Cabozantinib
A franchise small molecule drug candidate and targeted cancer therapy discovered by Exelixis, commercialized in multiple cancer indications and countries.
Cabozantinib (small molecule TKI)
Oral tyrosine kinase inhibitor developed and commercialized for multiple oncology indications; used in combination regimens in clinical development.
Cobimetinib (MEK inhibitor)
Internally discovered MEK pathway inhibitor that has been out‑licensed for development and commercialization.
Esaxerenone (mineralocorticoid receptor blocker)
Oral non‑steroidal selective mineralocorticoid receptor blocker developed via collaboration.
CABOMETYX
CABOMETYX (cabozantinib) is an oral targeted cancer therapy and multikinase inhibitor developed by Exelixis.
COMETRIQ
COMETRIQ (cabozantinib) is a prescription medicine used to treat advanced medullary thyroid cancer.
Cabozantinib
A franchise small molecule drug candidate and targeted cancer therapy discovered by Exelixis, commercialized in multiple cancer indications and countries.
Services
Evaluation, formation and management of collaborations, licenses and co‑development agreements for clinical‑stage and discovery assets.
Sponsorship and operational delivery of investigational clinical studies across Phase 1–3 for oncology compounds.
Safety reporting, adverse event management and medical information support for marketed products and investigational compounds.
Monetary charitable contributions, medical education support and sponsorships focused primarily on oncology and community initiatives.
Evaluation, formation and management of collaborations, licenses and co‑development agreements for clinical‑stage and discovery assets.
Sponsorship and operational delivery of investigational clinical studies across Phase 1–3 for oncology compounds.
Safety reporting, adverse event management and medical information support for marketed products and investigational compounds.
Monetary charitable contributions, medical education support and sponsorships focused primarily on oncology and community initiatives.
Expertise Areas
- Clinical trial management
- Translational medicine and biomarkers
- Small molecule drug discovery
- Biotherapeutics and ADC development
Key Technologies
- Antibody-drug conjugates (ADC)
- Bispecific antibodies
- Tyrosine kinase inhibitors (TKI)
- USP1 inhibition (small molecule target class)
News & Updates
Announcement regarding investor‑conference webcast events.
Corporate update on ongoing patent litigation matters.
Clinical update on a Phase 3 trial evaluating a next‑generation tyrosine kinase inhibitor in metastatic colorectal cancer.
Announcement regarding investor‑conference webcast events.
Corporate update on ongoing patent litigation matters.
Clinical update on a Phase 3 trial evaluating a next‑generation tyrosine kinase inhibitor in metastatic colorectal cancer.